Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VBI Vaccines Inc VBIVQ

Healthcare Biotechnology
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The... see more

Recent & Breaking News (PINL:VBIVQ)

VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Business Wire July 19, 2023

VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering

Business Wire July 6, 2023

VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants

Business Wire July 5, 2023

VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties

Business Wire July 5, 2023

VBI Vaccines Announces Results of Annual General Meeting

Business Wire June 23, 2023

VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Business Wire June 15, 2023

 VBI Vaccines Announces Poster Presentation at EASL 2023

Business Wire June 7, 2023

VBI Vaccines Reports First Quarter 2023 Financial Results

Business Wire May 15, 2023

VBI Vaccines Appoints Vaughn Himes to Board of Directors

Business Wire April 25, 2023

VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split

Business Wire April 4, 2023

VBI Vaccines Reports Full Year 2022 Financial Results

Business Wire March 13, 2023

VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat

Business Wire February 23, 2023

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

Business Wire February 15, 2023

VBI Vaccines Announces Health Canada Approval for PreHevbrio(TM) for the Prevention of Hepatitis B in Adults

Business Wire December 8, 2022

CEPI Boosts 'Coronavirus X' Vaccine Search With Expanded VBI Vaccines Deal

Business Wire December 6, 2022

VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

Business Wire November 22, 2022

VBI Vaccines to Participate in Upcoming Investor Conferences

Business Wire November 14, 2022

VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

Business Wire November 11, 2022

VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Business Wire November 10, 2022

VBI Vaccines to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference

Business Wire October 17, 2022